ETFChannel.com
REGN Description — Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.

REGN — Key Stats (updated 22 HRs, 8 MINs ago)
Company Name: 
Regeneron Pharmaceuticals, Inc.
Website: 
www.regeneron.com
Sector: 
Biotechnology
Number of ETFs Holding REGN: 
125
Total Market Value Held by ETFs: 
$9,058,528,740.2
Total Market Capitalization: 
$81,517,000,000
% of Market Cap. Held by ETFs: 
11.11%
ETFs Holding REGN
 ETF   REGN Weight   REGN Amount 
 VTI   0.15%   $1,858,060,062         
 VOO   0.19%   $1,491,018,028         
 QQQ   0.59%   $965,645,661         
 SPY   0.19%   $731,490,683         
 IVV   0.19%   $590,002,774         
 XLV   1.24%   $536,960,538         
 USMV   1.01%   $317,511,145         
 VTV   0.17%   $274,317,213         
 VUG   0.18%   $257,344,086         
 VHT   1.09%   $227,276,971         
List of all 125 ETFs holding REGN »
REGN — News
REGN — Price Chart
REGN — Current Quote
Quotes delayed 20 minutes

Email EnvelopeFree REGN Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
Avg. Broker Rec.

Buy (3.07 out of 4)
30th percentile
(ranked lower than approx. 70% of all stocks covered)

Analysts Forecast:
REGN Price Target

 Based on data provided by Zacks Investment Research via Quandl.com
REGN — Performance

ETFs Holding REGN | Regeneron Pharmaceuticals, Inc. | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2022, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.